Gamgee
Developer of personalized mRNA cancer treatment protocols for dogs, managing the end-to-end process from application to treatment in collaboration with veterinary oncologists.
About Gamgee
Gamgee is building an end to end platform for personalised mRNA cancer vaccines for dogs. We sequence a dog’s tumour and healthy DNA, identify mutations unique to its cancer, and design a vaccine that teaches the immune system what to attack. We manage the entire process- from vet intake and tissue collection through genomic analysis, vaccine production, treatment and response monitoring
Gamgee began with Rosie, founder Paul Conyngham’s dog. After surgery, chemotherapy and immunotherapy failed, Rosie was given months to live. Paul used AI and genomic analysis to identify targets in her tumour, then worked with scientists at UNSW to produce what is believed to be the first fully computationally designed mRNA cancer vaccine delivered to a dog. Following treatment, several tumours shrank significantly and her quality of life improved
We are now turning that one off effort into a repeatable clinical system. Gamgee is running clinical trials in Australia, working with vets, oncologists and specialised laboratories, and accepting cases globally. Our goal is to make personalised cancer treatment accessible to every dog that needs it- and use each case to improve the treatment for the next
Products
The first personalised cancer treatment protocol for dogs, designed to help their immune system fight back using mRNA vaccines built from the dog's own tumour.
Security and compliance
No security details published yet
Gamgee hasn't published certifications or security practices that we could find. Ask their team for audit reports.
Is this your company?
Claim the profile to keep facts current, answer buyers and submit evidence for the next ranking review.
Claim Gamgee